LANCASHIRE, England--(BUSINESS WIRE)--Oct 12, 2023--
Victrex plc, a pioneer in the development of PEEK biomaterial solutions, have today launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231011253520/en/
VICTREX PC101™ PEEK Granules and Film. (Photo: Business Wire)
VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications.
This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products.
VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago.
PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing.
Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond.
Speaking about the new product launch Ryan Elmore, Core Business Director, Medical at Victrex states, “The drug delivery market is a key focus for Victrex and one where we see huge potential for innovation and collaboration. We are thrilled to launch VICTREX PC101™, which meets the precise demands for non-implantable pharmaceutical contact and drug delivery device applications and will support drug delivery device manufacturers by creating easier pathways to market.”
Ryan Elmore continues, “Recent advances in drug delivery devices such as miniaturisation and increased drug viscosity call for designers to be able to access additional materials to meet the increasing manufacturing and performance challenges. Victrex PC101™ is perfectly placed to support them.”
To find out more about starting a drug delivery device product development projectcontact ustoday.
About Victrex
Victrex is an innovative world leader in high-performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy & industrial, electronics and medical. Every day, millions of people use products and applications which contain our sustainable materials – from smartphones, aeroplanes and cars to energy production and medical devices. With over 40 years experience, we develop world-leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and markets, enable environmental and societal benefits, and drive value for our shareholders.
Disclaimer
This information is provided “as is”. It is not intended to amount to advice. Use of the product is at the customer’s/user’s risk. It is the customer’s/user’s responsibility to thoroughly test the product in each specific application to determine its performance, efficacy and safety for each end-use product, device or other application and compliance with applicable laws, regulations and standards. Mention of a product is no guarantee of availability. Victrex reserves the right to modify products, data sheets, specifications and packaging. Victrex makes no warranties, express or implied (including, without limitation, any warranty of fitness for a particular purpose or of intellectual property non-infringement) and will not be liable for any loss or damage of any nature (however arising) in connection with customer’s/user’s use or reliance on this information, except for any liability which cannot be excluded or limited by law. This document may be modified or retracted at any time without notice to the customer/user.
Victrex Manufacturing Limited (or another member of the Victrex group) is the owner or the licensee of all intellectual property rights in and to this document including the following trademarks, VICTREX, INVIBIO, JUVORA, APTIV, 450G, PEEK-OPTIMA, SHAPING FUTURE PERFORMANCE, LMPAEK, TRIANGLE (Device). All rights are protected by intellectual property rights including copyright under relevant national and international intellectual property laws and treaties. All rights reserved. Copyright © Victrex Manufacturing Limited 2023.
View source version on businesswire.com:https://www.businesswire.com/news/home/20231011253520/en/
CONTACT: Victrex media contact
Laura Delooze, Marketing Communications Manager
Laura.delooze@victrex.com, Phone +44 1253 898024
Group media or Investor Relations enquiries
Andrew Hanson, Director of Investor Relations, Corporate Communications and ESG
ahanson@victrex.com, Phone +44 1253 898121
KEYWORD: EUROPE UNITED KINGDOM ASIA PACIFIC
INDUSTRY KEYWORD: MEDICAL DEVICES PACKAGING ENGINEERING CHEMICALS/PLASTICS AEROSPACE MANUFACTURING BIOTECHNOLOGY HEALTH PHARMACEUTICAL
SOURCE: Victrex plc
Copyright Business Wire 2023.
PUB: 10/12/2023 03:41 AM/DISC: 10/12/2023 03:42 AM
http://www.businesswire.com/news/home/20231011253520/en
